Negative-pressure wound therapy and early pedicle flap reconstruction of the chest wall after epirubicin extravasation.
OBJECTIVE
Accidental extravasation is a serious iatrogenic injury among patients receiving anthracycline-containing chemotherapy. The aim of this work is to present a combination therapy for chest wall reconstruction following epirubicin extravasation.


METHODS
Herein, we report a 68-year-old woman with massive soft tissue necrosis of the anterolateral chest wall after epirubicin extravasation from a port implanted in the subclavicular area.


RESULTS
The necrotic tissue was resected, the port was removed, and negative-pressure wound therapy was applied. Three weeks later, a latissimus dorsi pedicle flap was successfully used to cover the defect.


CONCLUSIONS
To the best of the authors' knowledge, this is the first report of a strategy comprising the combination of negative-pressure wound therapy and a latissimus pedicle flap for reconstruction of the chest wall after soft tissue necrosis following epirubicin extravasation.
Department of Plastic Surgery, Helios Clinic Wuppertal, University Hospital, Witten-Herdecke - Germany.
Marios
M
Papadakis
Department of Plastic Surgery, Helios Clinic Wuppertal, University Hospital, Witten-Herdecke - Germany.
Afshin
A
Rahmanian-Schwarz
Department of Plastic Surgery, Helios Clinic Wuppertal, University Hospital, Witten-Herdecke - Germany.
Marzena
M
Bednarek
Department of Plastic Surgery, Helios Clinic Wuppertal, University Hospital, Witten-Herdecke - Germany.
Mohamed
M
Arafkas
Department of Plastic Surgery, Helios Clinic Wuppertal, University Hospital, Witten-Herdecke - Germany.
Philipp
P
Holschneider
Department of Plastic Surgery, Helios Clinic Wuppertal, University Hospital, Witten-Herdecke - Germany.
Gunnar
G
Hübner
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002405:Catheterization, Central Venous; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007049:Iatrogenic Disease; D007262:Infusions, Intravenous; D009336:Necrosis; D054843:Negative-Pressure Wound Therapy; D019651:Plastic Surgery Procedures; D064171:Superficial Back Muscles / Q000637:transplantation*; D013524:Surgical Flaps; D035441:Thoracic Wall / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome; D014945:Wound Healing
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin